Fennec Pharmaceuticals (TSX:FRX) Growth Rank : 0 (As of Dec. 12, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Growth Rank?

Fennec Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Fennec Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

FENC:USA RV41:Germany

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Executives

Robert Christopher Andrade	Senior Officer
Rostislav Christov Raykov	Director, Senior Officer
Adrian J. Haigh	Senior Officer
Chris Anigeron Rallis	Director
Khalid Islam	Director